type: misc

label: url

en: 多職種連携教育で推進する医療教育学

ja: 多職種連携教育で推進する医療教育学

en: 日本栄養学教育学会雑誌

ja: 日本栄養学教育学会雑誌


en: 医学部における教育評価の特殊性 ―臨床医学の面から―

ja: 医学部における教育評価の特殊性 ―臨床医学の面から―

en: 医学教育

ja: 医学教育


en: 単心室症患児の開心術後にフェイススケールを用いて心臓リハビリテーションを試みた1症例

en: Heart

ja: 心臓


en: これからの医学教育∼総合診療への期待∼

ja: これからの医学教育∼総合診療への期待∼

en: 日本プライマリ・ケア連合学会四国支部論文集

ja: 日本プライマリ・ケア連合学会四国支部論文集


en: クリニカル・クラークシップの現状と展望∼求められる指導医像とは∼

ja: クリニカル・クラークシップの現状と展望∼求められる指導医像とは∼

en: 徳島市民病院医学雑誌

ja: 徳島市民病院医学雑誌


en: Efficacy of percutaneous transluminal renal angioplasty for renovascular hypertension complicated with heart failure

ja: 心不全を合併した腎血管性高血圧に対する経皮的腎動脈形成術の有効性(第11回若手奨励賞受賞論文)

en: 【Background】 Percutaneous transluminal renal angioplasty (PTRA) is recommended for patients with heart failure due to renovascular hypertension ; however, the clinical characteristics of the patients and the effects of PTRA on heart failure and cardiorenal function have not been elucidated. 【Methods】 We retrospectively analyzed data for 4 PTRA-treated patients (male/female, 1/3 ; mean age, 70.0±10 years ; mean left ventricular ejection fraction, 51.5±15.2%) with heart failure due to renovascular hypertension and evaluated the effects of PTRA on heart failure and cardiorenal function 6 months after treatment. 【Results】 All patients had pro-arteriosclerotic diseases including diabetes mellitus, essential thrombocythemia, heparin cofactor II deficency, metabolic syndrome, and familial hypercholesterolemia, and 3 patients had ischemic heart disease. No abdominal bruit was heard and mean plasma renin activity was 4.5±3.6 ng/ml/hr, which was not elevated, contrary to expectation. All contralateral kidneys of PTRA were nonfunctioning, suggesting bilateral kidneys were disturbed in all patients. In all patients, PTRA was successfully performed and resolved heart failure. PTRA resulted in decreases in systolic blood pressure from 157±18 to 124±8.6 mmHg, mean serum creatinine from 3.2±2.6 to 2.7±2.2 mg/dl, and mean BNP from 919±998 to 243±291 pg/ml at 6 months after treatment. PTRA did not change left ventricular ejection fraction, a parameter of systolic fraction evaluated by an echocardiogram ; however, PTRA improved E/e', a parameter of left ventricular diastolic fraction, from 16.1±5.2 to 9.7±3.7. None of the patients were hospitalized due to heart failure during the 6-month period after PTRA. 【Conclusions】 Patients with heart failure with cardiovascular risk factors should be screened for renovascular hypertension regardless of abdominal bruit or plasma renin activity. PTRA is effective for resolving heart failure and for improving renal and cardiac diastolic functions in patients with renovascular hypertension complicated with heart failure.

en: Shikoku Acta Medica

ja: 四国医学雑誌


en: Pentraxin-3 --- A potential novel biomarker detecting vulnerable plaque and predicting prognosis in acute myocardial infarction

en: Circulation Journal

ja: Circulation Journal


en: Late Gadolinium Enhancement of Cardiac Magnetic Resonance and Computed Tomography of Skeletal Muscle at Lower Legs in Female Carriers of Duchenne Muscular Dystrophy

ja: Duchenne型筋ジストロフィー女性保因者における心臓MRIガドリニウム遅延造影と下腿筋CT

en: Japanese Journal of National Medical Services

ja: 医療


en: Effects of Statins on Cardiorenal Syndrome.

en: Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.

en: International Journal of Vascular Medicine


en: Effects of androgens on cardiovascular remodeling.

en: Androgens, the male sex hormones, exert various biological effects on many target organs through the transcriptional effects of the nuclear androgen receptor (AR). ARs are expressed not only in classical target organs, such as the brain, genital organs, bone, and skeletal muscles, but also in the cardiovascular system. Because the female sex hormones estrogens are well known to protect against cardiovascular disease, sex has been considered to have a significant clinical impact on cardiovascular mortality. However, the influence of androgens on the cardiovascular system has not been fully elucidated. To clarify this issue, we analyzed the effects of administration of angiotensin II and doxorubicin, an anticancer agent, in a loading model in male wild-type and AR-deficient mice. In this review, we focus on the actions of androgens as potential targets for the prevention of cardiovascular diseases in males.

en: The Journal of Endocrinology

ja: The Journal of Endocrinology


en: Education of Physicians in Specialties

ja: 後期専門研修医の教育のあり方

en: The Journal of Japan Society for Clinical Anesthesia

ja: 日本臨床麻酔学会誌


en: Transforming Growth Factor-1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.

en: Transforming growth factor-1 (TGF-1) is a polypeptide member of the transforming growth factor superfamily of cytokines. It is a secreted protein that performs many cellular functions including control of cell growth, cell proliferation, cell differentiation and apoptosis. In the cardiovascular system, TGF-1 plays pivotal roles in the pathogenesis of hypertension, restenosis after percutaneous coronary intervention, atherosclerosis, cardiac hypertrophy and heart failure. In addition, TGF-1 has been shown to be increased in adipose tissue of obese subjects with insulin resistance. Furthermore, TGF-1 is a potent initiator of proliferation of renal mesangial cells leading to chronic kidney disease. Some currently available agents can manipulate TGF-1 expression leading to amelioration of cardiovascular diseases. Thus, an understanding of interactions between chronic kidney disease and metabolic syndrome and the development of cardiovascular diseases is an important issue, and attention should be given to TGF-1 as a crucial factor for regulation and modulation of those pathological conditions.

en: Cardiology Research and Practice

ja: Cardiology Research and Practice


en: Heparin Cofactor II as a Novel Vascular Protective Factor Against Atherosclerosis.

en: Heparin cofactor II (HCII) specifically inhibits thrombin action at the site of vascular wall injury. We encountered a congenital HCII deficiency patient with advanced multiple atherosclerotic lesions. This patient led us to conduct clinical studies to examine the role of HCII against atherosclerosis. We found that the incidence of in-stent restenosis after percutaneous coronary intervention, severity of carotid atherosclerosis and prevalence of peripheral arterial disease are inversely associated with plasma HCII activity. In order to clarify the vascular protective action of HCII, we generated HCII- deficient mice by gene targeting. In contrast to a previous study, HCII(-/-) mice were embryonically lethal. In HCII(+/-) mice, accelerated intimal hyperplasia and frequent thrombosis were observed after cuff or wire injury of femoral arteries. The number of protease-activated receptor-1 (PAR-1) -positive cells and the gene expression levels of inflammatory cytokines and chemokines were increased in the thickened vascular walls of HCII(+/-) mice. The accelerated intimal hyperplasia in HCII+/- mice with vascular injury was attenuated by human HCII administration. Furthermore, HCII deficiency exaggerated aortic plaque formation with increased oxidative stress in apolipoprotein E(-/-) mice. These results demonstrate that HCII protects against thrombin-induced vascular remodeling in both humans and mice and suggest that HCII is a predictive biomarker and therapeutic target for atherosclerosis.

en: Journal of Atherosclerosis and Thrombosis


en: 徳島大学の医学教育を考えるー臨床医学教育―

ja: 徳島大学の医学教育を考えるー臨床医学教育―

en: Shikoku Acta Medica


en: NO bioavailability

ja: NO bioavailability

en: CLINICAL CALCIUM

ja: CLINICAL CALCIUM


en: 血管内皮細胞に対するステロイドの影響と大腿骨頭壊死

ja: 血管内皮細胞に対するステロイドの影響と大腿骨頭壊死

en: 整形外科

ja: 整形外科


en: 内分泌疾患

ja: 内分泌疾患

en: Internal Medicine

ja: 臨床雑誌 内科


en: Gene Analysis in Patients with Muscular Dystrophy --- α-Sarcoglycan(Adhalin) Gene Mutations in Patients with Malignant Limb-girdle Muscular Dystrophy

ja: 筋ジストロフィーの遺伝子診断 --- とくに悪性肢帯型筋ジストロフィーにおけるα-sarcoglycan(adhalin)の遺伝子異常について

en: The Official Journal of Japanese Society of Laboratory Medicine

ja: 臨床病理


en: Adhalin欠損悪性肢帯型筋ジストロフィーにおけるadhalin遺伝子の異常

ja: Adhalin欠損悪性肢帯型筋ジストロフィーにおけるadhalin遺伝子の異常

en: Annual Review 神経 1996

ja: Annual Review 神経 1996


en: 悪性肢帯型筋ジストロフィーにおけるadhalin遺伝子の異常

ja: 悪性肢帯型筋ジストロフィーにおけるadhalin遺伝子の異常

en: 神経内科

ja: 神経内科


en: 筋疾患

ja: 筋疾患

en: Monthly Book Orthopaedics

ja: オルソペディクス


en: 症例研究 ミトコンドリア脳筋症

ja: 症例研究 ミトコンドリア脳筋症

en: Medical Student

ja: Medical Student


en: Involvements of HTLV-1 and HTLV-2 in the Pathogenesis Hashimoto Thyroiditis

en: 80 years of Hashimoto Disease

ja: 80 years of Hashimoto Disease


en: ドプラーエコー X,心筋症

ja: ドプラーエコー X,心筋症


en: 2017 Annual Report on Faculty Development Programs at Tokushima University

ja: 2017年度徳島大学全学FD推進プログラムの実施報告

en: Journal of University Education Research

ja: 大学教育研究ジャーナル

misc_type: others


en: 2016 Annual Report on Faculty Development Programs at Tokushima University

ja: 2016年度徳島大学全学FD推進プログラムの実施報告

en: 全学FD 推進プログラムは2002 年度から開始され，FD の体系化，組織化，日常化等を推進してきた．2016 年度は，例年開催している，「授業設計ワークショップ」，「授業参観・授業研究会」，「大学教育カンファレンスin 徳島」，「ティーチング・ポートフォリオ作成ワークショップ」の他に，各学部等におけるFD の実態を把握し，成果や課題を明らかにした上で，ニーズの明確化，今後の学部等FD と総合教育センターの支援の在り方について検討するために，「質保証のための分野別ワークショップ」を開催した．また，大学教育再生加速プログラムに関連するSIH 道場FD・説明会の実施や学内でアクティブ・ラーニングを推進するためにLED カフェ等を実施した．各プログラムについて概要を記載し，アンケート結果等から成果と今後の課題について考察する．